Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about finding a trustworthy and affordable source for RU58841 in Europe, with a comparison between Anagenic and Actifolic. The user seeks experiences from others in the EU to avoid receiving water instead of the product.

The conversation is about the potential availability of GT20029 on the black market and whether users would try it. Participants advise waiting for phase 3 trial results to ensure safety and efficacy.

A 20-year-old started taking 1mg oral finasteride and 3mg oral minoxidil every other day for hair loss. They plan to focus on their hair and health over the summer and will update in November.

A 20-year-old experiencing diffuse thinning is using a regimen of oral minoxidil, dutasteride, finasteride, and ketoconazole to address hair loss. They are considering increasing the minoxidil dosage or adding topical treatments due to minimal shedding observed after 16 days.

GT20029 is discussed as a potential treatment for androgenetic hair loss by targeting androgen receptors, unlike finasteride which reduces DHT broadly. Concerns include its effectiveness, genetic variations in androgen receptors, and availability, with some skepticism about its potential as a true alternative.

Eirion Therapeutics is recruiting for phase 1 of ET-02 in Texas, which showed promising hair growth results in non-clinical studies. ET-02 demonstrated significantly more hair growth compared to Minoxidil.

The conversation discusses disappointment with the hair loss treatment KX-826 but notes that the company Kintor is still focused on developing and commercializing it, as stated in their 2023 annual report. The user questions the effectiveness of KX-826 in comparison to minoxidil's role in improving hair thickness and appearance.

The conversation is about purchasing KX-826 (Pyrilutamide) on Amazon, now called Koshine. A user mentioned their order is expected to arrive between August 22 and September 13.

A 19-year-old with NW2-2.5 hair loss is starting finasteride soon, considering low dosages of 0.25mg daily or 0.5mg 3-5 times a week. They are also using derma stamping, ketoconazole shampoo, ACV washes, and various oils to maintain hair quality and reduce scalp itch.

KX826 is considered a legitimate option for those who cannot use finasteride or dutasteride, but many users report it as ineffective compared to RU58841. RU58841 is favored by some due to anecdotal evidence of effectiveness, despite the lack of published clinical data.

The conversation is about comparing the effectiveness of fluridil and clascoterone in preventing hair loss and inquiring about their use as standalone treatments. There is a question about the concentration of the fluridil brand for efficacy.

GT20029 is anticipated to start phase III trials in Q3 2026, with potential public availability around 2029-2030.

Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.

The conversation is about the anticipation and uncertainty regarding the release of GT20029 Phase 2 results for hair loss treatment. Users express hope for its effectiveness and minimal side effects compared to other treatments like Pyri and HMI115.

A 20-year-old experiencing diffuse thinning for two years has been using topical minoxidil and finasteride but hasn't noticed significant regrowth or reduced hair loss. They are seeking advice on whether to switch treatments, with suggestions including oral minoxidil, topical finasteride, and maintaining scalp health.

A 20-year-old is experiencing hair loss and has tried oral and topical minoxidil, finasteride, and is considering dutasteride and a hair transplant. They feel frustrated and hopeless due to the lack of results and its effect on their mental health.

GT20029 is a potential treatment for androgenetic alopecia, addressing the root cause by targeting androgen receptors, unlike Minoxidil or Finasteride. It is seen as a preventative measure rather than a regrowth agent, with hopes for market release soon.

Procyanidin B2, a compound derived from Annurca apples, as a potential treatment for pattern hair loss. Several clinical studies were mentioned, which found that procyanidin B2 could increase hair growth, density, and keratin content. Other treatments such as Minoxidil, Finasteride, and RU58841 were not discussed.

A user ordered Alpha Plus from Anagenica, expecting it to contain specific percentages of Fin, Estradiol, Minoxidil, and CB0301. However, the received product's label showed different percentages, including a surprising 25% CB, leading the user to question its safety and accuracy.

Visible hair improvement after 10 weeks using minoxidil, estradiol enanthate, acetophenide algestone, and bicalutamide. The user is a 25-year-old male with reduced testosterone levels, expressing a preference for less masculinity.

TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.

PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.

PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.

Stefano, a 20-year-old male, experienced significant hairline shedding and thinning after using topical Minoxidil, along with rosemary/jojoba oil, biotin tablets, caffeine shampoo, and a dermaroller. He is uncertain whether to continue the treatment in hopes of regrowth or stop and potentially return to his original hair condition, while a reply suggests using finasteride or dutasteride to address the underlying cause of hair loss.

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.

Kintor's Pyrilutamide (KX-826) showed hair growth in Chinese Phase III trials but did not significantly outperform placebo. The treatment was safe with no major adverse reactions reported.

A 20-year-old has been using topical minoxidil and finasteride for 6 months but sees little hair growth, especially on the temples. They are considering switching to oral dutasteride and minoxidil due to lack of progress.

The conversation is about hair loss treatments, specifically the anticipation for the release of a new treatment, GT20029, by 2028. Users are discussing their experiences with current treatments like finasteride and dutasteride, and the potential of future treatments, including FAK inhibitors and verteporfin trials.

KX-826 Pyrilutamide 1% is launching soon, and users are discussing its potential benefits and drawbacks compared to other treatments like Minoxidil and finasteride. Some users are skeptical about its effectiveness, while others are hopeful it will be a safer alternative.

PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.